He is internationally recognized as a leader in the development of novel proteomics methods and in their application in biology, chemistry, and medicine.
Carr and his group of staff scientists and postdoctoral fellows collaborate with scientists throughout the Broad Institute community (comprised of MIT, Harvard University Faculty of Arts and Sciences, Harvard Medical School, and the 17 Harvard-affiliated hospitals) to apply state-of-the-art proteomics technology to address compelling questions in biology, chemistry, and clinical medicine.
Research in his laboratory focuses on developing and applying new technologies to quantify proteins and their modifications and interaction partners in tissues, cells, and biofluids with high sensitivity and specificity; improving informatics for peptide and protein assignment using mass spectrometry (MS) data; and integration of MS-derived data with genomic data to understand disease biology and drug effects. The group also has a major focus on the discovery and quantitative verification of biomarkers for major diseases including cancer and cardiovascular and infectious diseases, as well as pharmacodynamics markers of drug response.